Stephen Worsley, M.B.A
Senior Vice President, Business Development
Stephen Worsley serves as senior vice president business development at Indi Molecular. He joined the company in October 2017. Worsley is a seasoned life sciences executive who most recently at Peregrine Pharmaceutical as the VP business development. His business development leadership spans more than 25 years in roles of increasing impact in bioscience and drug discovery and development.
As a business development executive, Worsley has led negotiation of transformative and award-winning technology and product partnerships for leading therapeutics companies, focused in the protein, antibody and antibody surrogate arena. Among others, these include global co-development agreements on behalf of Abgenix with Immunex/Wyeth (now Amgen) with Vectibix® (panitumumab); on behalf of Zosano Pharmaceutical with Asahi Kasei Pharma Corporation (AKP) on ZP-PTH; on behalf of Raven Biotechnologies with Macrogenics (leading to the merger of the two companies); and also on behalf of Raven with Abbott a collaboration focused on five key antibody development programs.
Prior to his leadership role at Peregrine, Worsley served as chief business officer for Centrose Pharmaceutical and VP business development for Intrexon. Earlier in his career he held the position of VP business development at Zosano Pharmaceutical and Raven Biotechnologies. He also served as director of business development for several successful startups, including Abgenix (acquired by Amgen), Tripos Drug Discovery (acquired by PharSight) and OHM Technologies (acquired by The Carlyle Group).
Worsley holds an MBA from the University of Washington and a BS from the University of Utah.